Rockefeller Capital Management L.P. Sells 3,260 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rockefeller Capital Management L.P. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 94,744 shares of the biopharmaceutical company's stock after selling 3,260 shares during the period. Rockefeller Capital Management L.P. owned about 0.09% of Regeneron Pharmaceuticals worth $67,505,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Monetary Management Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 13.3% in the fourth quarter. Monetary Management Group Inc. now owns 1,787 shares of the biopharmaceutical company's stock valued at $1,273,000 after buying an additional 210 shares during the period. Coign Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $484,000. Heritage Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $1,717,000. Kennedy Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 14.5% during the 4th quarter. Kennedy Capital Management LLC now owns 5,156 shares of the biopharmaceutical company's stock valued at $3,673,000 after purchasing an additional 652 shares in the last quarter. Finally, Phoenix Financial Ltd. grew its stake in Regeneron Pharmaceuticals by 19.0% during the fourth quarter. Phoenix Financial Ltd. now owns 2,103 shares of the biopharmaceutical company's stock worth $1,498,000 after purchasing an additional 336 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $13.88 during midday trading on Friday, reaching $563.16. The company had a trading volume of 827,663 shares, compared to its average volume of 711,859. The stock has a market cap of $61.57 billion, a P/E ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company's 50 day moving average price is $647.99 and its 200 day moving average price is $743.86.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Bank of America dropped their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $963.56.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.